Rhenium Liposome Treatment
Small molecule
Rhenium Liposome Treatment is one of 36 small molecule programs targeting Glioma. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
394 competitors in Glioma
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsPhase 3
Bicnu
MMelissa K Accordino
Phase 3
Vepesid
AAvyxa
Phase 3
Photofrin
PPinnacle Biologics Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Velban
EEastern Cooperative Oncology Group
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Modeyso
CChimerix
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rhenium Liposome Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- PPlus Therapeutics